| FzioMed,
Inc. to Exhibit Oxiplex Adhesion Barrier Technology at European
Surgery Conferences.
FzioMed will exhibit at the Annual International
Conference of The International Society of Orthopaedic Surgery
and Traumatology (SICOT) to be held August 30 - September 1, 2001
at the Palais des Congres in Paris, France. SICOT is the world
orthopaedic organization; a global association of specialized
surgeons and researchers devoted to the advancement of orthopaedics
and traumatology on an international level.
The company will also exhibit at EuroSpine 2001,
the 3rd Annual Meeting of the Spine Society of Europe (SSE) to
be held September 1 - 8, 2001 at the Swedish Exhibition Congress
Centre in Gothenberg, Sweden. The Spine Society of Europe is the
leading society in Europe for the research, prevention and treatment
of conditions of the spine.
FzioMed was recently awarded the CE Mark certification
for its Oxiplex adhesion barrier technology for use in spine,
abdominal and pelvic surgery. The CE Mark allows FzioMed's Oxiplex/SP
Gel and Oxiplex Adhesion Barrier Film products to be marketed
throughout the European Community.
Oxiplex/SP Gel and Oxiplex Film are
bioabsorbable adhesion barriers that are applied during surgery
to reduce post-operative internal scarring, also known as post-surgical
adhesions. Post-surgical adhesions are a leading complication
of many surgical procedures. Oxiplex/SP Gel is only the
second bioabsorbable adhesion barrier product to receive CE Mark
for use in spine surgery. Oxiplex Adhesion Barrier Film
is for use in abdominal and pelvic surgery. The company is also
developing products for cardiac surgery and tendon surgery.
FzioMed is a privately held biomedical company engaged
in the development and commercialization of advanced, bioabsorbable
products based on the company's patented Oxiplex technology.
Oxiplex is an innovative polymer technology that is formulated
for a variety of targeted medical indications and markets. Products
in development using Oxiplex include those for the prevention
of post-surgical adhesions, hemostasis during surgery, osteoarthritis
and drug delivery. FzioMed products are at various stages of clinical
and pre-clinical development in the United States and are directed
towards high growth markets in the rapidly growing field of biosurgery
products.
Oxiplex is a registered trademark of FzioMed,
Inc.
Back to News Articles
|